Akebia Therapeutics Ends Licensing Deal, Commits to Repayment Plan
PremiumCompany AnnouncementsAkebia Therapeutics Ends Licensing Deal, Commits to Repayment Plan
2M ago
Akebia, CSL Vifor enter termination agreement of the Vafseo license agreement
Premium
The Fly
Akebia, CSL Vifor enter termination agreement of the Vafseo license agreement
2M ago
Akebia Therapeutics Welcomes New CFO and Financial Strategist
Premium
Company Announcements
Akebia Therapeutics Welcomes New CFO and Financial Strategist
3M ago
Akebia Therapeutics (AKBA) Q1 Earnings Cheat Sheet
PremiumPre-EarningsAkebia Therapeutics (AKBA) Q1 Earnings Cheat Sheet
5M ago
Akebia price target raised to $6 from $5 at H.C. Wainwright
Premium
The Fly
Akebia price target raised to $6 from $5 at H.C. Wainwright
6M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
6M ago
Akebia Therapeutics Confronts Financial Reporting Flaw: Inventory Management Weakness Sparks Investor Concern
PremiumCompany AnnouncementsAkebia Therapeutics Confronts Financial Reporting Flaw: Inventory Management Weakness Sparks Investor Concern
6M ago
Akebia Therapeutics Announces CFO Transition and Interim Plan
Premium
Company Announcements
Akebia Therapeutics Announces CFO Transition and Interim Plan
6M ago
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Premium
Press Releases
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100